To explore potential clinical benefits of combination therapy with PARPis and cholesterol-lowering drugs, we investigated the effect of statins, HMGCR inhibitors, when administered as concomitant medication to patients with ovarian cancer enrolled in three niraparib monotherapy registrational clinical trials. Here, HMGCR is linked to ovarian cancer.